Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

Description

This is a phase 0 clinical trial of molecular biomarkers in women with uterine cervix cancer. Women receive standard-of-care radiochemotherapy followed by brachytherapy. Blood samples are obtained to detect circulating levels of deoxyribonucleotides, human papillomavirus DNA, and circulating tumor cells.

Conditions

Uterine Cervix Cancer

Study Overview

Study Details

Study overview

This is a phase 0 clinical trial of molecular biomarkers in women with uterine cervix cancer. Women receive standard-of-care radiochemotherapy followed by brachytherapy. Blood samples are obtained to detect circulating levels of deoxyribonucleotides, human papillomavirus DNA, and circulating tumor cells.

Phase 0 Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

Condition
Uterine Cervix Cancer
Intervention / Treatment

-

Contacts and Locations

Lexington

Markey Cancer Center, Lexington, Kentucky, United States, 40536

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Presence of another concurrent active invasive malignancy
  • * Prior invasive malignancy diagnosed within the last three years except for \[1\] non-melanoma skin cancer or \[2\] prior in situ carcinoma of the cervix
  • * prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Denise Fabian,

Denise Fabian, MD, PRINCIPAL_INVESTIGATOR, University of Kentucky

Study Record Dates

2025-12-31